Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ConvaTec acquires Unomedical
The combination is expected to create a company with $1.6 billion in annual sales with a significantly expanded global footprint. The combined company will be known as ConvaTec
The combination is expected to create a company with $1.6 billion in annual sales with a significantly expanded global footprint. The combined company will be known as ConvaTec
Ipsogen SA has also appointed Ms Hertzberg as its vice president of corporate business development. Immediately prior to joining Ipsogen, Ms Hertzberg served as general manager of global
The Petal study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups – elagolix 150mg once daily, elagolix 75mg twice daily, or depo-subQ provera
The agreement grants Dr Reddy’s exclusive rights to distribute Cosmederm Technologies’s unique skin care products throughout India. Cosmederm’s proprietary technology allows for the formulation of highly potent, non-irritating
The study compared the current standard of care for acute coronary syndrome (ACS), including aspirin and clopidogrel, with apixaban on top of the standard of care. The six-month
However, GlaxoSmithKline (GSK) is retaining rights to Entereg for postoperative ileus (POI), and the companies will continue to collaborate on the development and commercialization of Entereg for POI
Olympia is designed to analyze real-world clinical outcomes data for Boston Scientific’s second-generation Taxus Liberte paclitaxel-eluting coronary stent system in the treatment of patients with coronary artery disease.
Under the terms of their 2006 collaboration agreement, the clinical program for ITMN-191 is now being transitioned to Roche which, starting in Phase II, will have primary responsibility
The product line includes radiation sources and standards used in a variety of areas for calibration, measurement, analysis and control. The transaction is valued at approximately $6 million
This Phase I trial will assess the safety and pharmacokinetic profile of CVT-3619 in healthy volunteers. The Phase I program will provide early data on the compound’s potential